Nitric oxide synthase gene therapy has been shown to be effective at inducing apoptosis in experimental tumours and sensitizing them to radiotherapy. We have also shown that expression of inducible nitric oxide synthase (iNOS) can be effectively restricted to the tumour volume by the use of the radiation inducible promoter (WAF1) to drive the transgene in clinically relevant protocols. A synthetic construct (pE9), incorporating nine radiosensitive CArG elements from the Egr1 promoter, has recently been developed for cancer gene therapy. We have now investigated basal gene expression of transgenes driven by this promoter to assess its suitablility for use in iNOS gene therapy protocols in vivo. Transfection of human microvascular endothelial cells (HMEC-1) with pE9iNOS, using a cationic lipid vector, resulted in progressively increasing (o5-fold) levels of iNOS protein expression up to 8 h after transfection. Transfection of an ex vivo rat artery preparation with pE9iNOS caused 83% inhibition of response to the vasoconstrictor phenylephrine (PE). CMVi-NOS transfection also reduced response to PE, but by only 52%. A single injection of 25 mg of pE9iNOS DNA in a lipid vector into the centre of a murine sarcoma (RIF1) induced iNOS protein expression by four-fold and increased nitrite concentration eight-fold. This caused a 7-day delay in tumour growth and was more effective than the constitutive CMVdriven construct. Our data suggest that generation of NO K , as a result of iNOS overexpression, is capable of further activating the E9 promoter, through a positive feedback loop, yielding stronger and sustained levels of NO K . This pE9iNOS combination may, therefore, be particularly useful in an anticancer gene therapy strategy as its antitumour effect in vivo was clearly superior to that of the strong constitutive promoter, CMV.
Introduction
Controlled regulation of transgene expression is an important component of targeted gene therapy strategies. This regulation can be achieved by use of tissue-specific transcriptional control elements such as those found within the 5 0 promoter regions of genes expressed in hepatocytes, 1 melanocytes 2 or neurones. 3 Specific characteristics of tumour cells 4, 5 or of the tumour microenvironment 6 can also be targeted, but it is also preferable in a therapeutic strategy to include a level of exogenous control over the magnitude and duration of gene expression to enhance targeting specificity. To this end much research has focused on externally inducible promoters including those activated by heat, 7, 8 radiation 9 and drugs. 10 Radiation is one of the most important modalities used to treat solid tumours, so it is logical to incorporate radiation-inducible elements into transgene constructs to be used in gene therapy protocols in combination with radiotherapy. Previous research in our laboratory has shown that the p21 WAF1/CIP1 promoter can be used to drive expression of inducible nitric oxide synthase (iNOS) after a 4 Gy dose of X-rays. The resulting product, nitric oxide (NO K ), caused significant vasodilation in isolated arteries, 11 and lead to an increase in sensitivity to subsequent radiation therapy in both a murine fibrosarcoma and the human colon HT29 xenograft. 12, 13 While the WAF1 promoter has the important characteristic of being silent in unirradiated normal tissues, 13 it is an intrinsically weak promoter, and shows little induction at the most clinically relevant radiation dose of 2 Gy. Our previous experiments with this promoter were important nonetheless in establishing the principle that iNOS gene therapy driven by a radiation-inducible promoter could achieve impressive enhancement of tumour radiation response in vivo. 13 However, a stronger promoter, inducible by a dose of 2 Gy, would be desirable for clinical application.
A 10 base pair sequence in the Egr1 gene, which confers radiation inducibility -the CArG element has been identified. 14 The native Egr1 gene promoter (E425: containing six CArG elements) in combination with the herpes simplex virus thymidine kinase gene has been used to sensitise glioma cells to ganciclover after exposure to a single 20 Gy dose of X-rays. 15 An E425/ TNF-a construct has been used in human epithelial SQ-20B tumour xenografts; 90% regression was observed after fractionated X-ray treatment totalling 40 Gy. 16 Similar results were obtained using a murine fibrosarcoma model. 17 Scott and colleagues have developed novel synthetic promoters containing CArG elements and a novel molecular switch involving a Cre/lox P site-specific recombination system. [18] [19] [20] This group also incorporated hypoxia-responsive elements from the erythropoietin, phosphoglycerate kinase and vascular endothelial growth factor (VEGF) genes into a novel chimeric promoter in combination with CArG elements. 21 This study describes the evaluation of the basal and NO K -inducible activity of a synthetic promoter (E9), incorporating 9 CArG elements, to drive expression of the iNOS gene for experimental gene therapy. Since reactive oxygen species have been shown to activate CArG elements, 22 we proposed that the relatively high levels of NO K present endogenously in tumours compared with normal tissues might be capable of positively activating pE9iNOS, leading to enhanced promoter activation and establishing a positive feedback loop. We, therefore, examined the basal expression or 'leakiness' of this promoter, the level of gene expression it produced in the absence of irradiation, in human microvascular endothelial cells (HMEC-1), using iNOS and green fluorescent protein (GFP) as reporter genes. We also describe the superiority of CArG over CMV driven iNOS contructs using tumour growth delay assays in the murine RIF-1 fibrosarcoma as an end point.
Results
In vitro analysis of pE9iNOSpuro vector HMEC-1 cells were transfected with the pE9iNOS construct and samples extracted for Western blot analysis at various times (0, 1, 2, 4 and 8 h) after transfection. Cells were also transfected with the pE9GFP construct as a control, as an alternative measure of basal promoter activity driving a different transgene. Additionally, cells transfected with the pE9iNOS construct were exposed to the iNOS inhibitor L-NMMA to establish if generation of NO K from iNOS was inducing the pE9 promoter.
Cells transfected with the pE9iNOS construct showed progressively increasing iNOS protein expression for up to 8 h after transfection (Figure 1 ). By that time the iNOS protein level was four-fold higher than that observed in cells exposed to the lipofection agent only (P ¼ 0.04, ANOVA). Furthermore, cells transfected with pE9iNOS exhibited iNOS protein levels at least as high as those in cells transfected with the constitutively expressing CMViNOS construct. By contrast, cells transfected with a pE9GFP construct showed no detectable levels of reporter protein induction. The addition of the NOS inhibitor L-NMMA to cells at the time of transfection with pE9iNOS inhibited iNOS protein production. iNOS protein levels were not significantly different to those of cells exposed to lipofection agent alone (P ¼ 0.56, ANOVA). It was clear, however, that the stress involved in exposure of cells to serum-free medium, as required for transfection, did stimulate low level iNOS expression when compared to cells left undisturbed in normal serum-containing medium (Figure 1 ).
Dilation of mammalian artery by pE9iNOS transfection
A section of rat artery was cannulated and placed on a perfusion apparatus as described in our previous studies. 11 Arteries were first exposed to various gene therapy constructs and perfusion pressure (as a measure of vasodilation) measured. The arteries were then perfused with the a 1 agonist phenylephrine (PE) to cause constriction, and perfusion pressure remeasured. This system enabled the ability of two gene therapy systems to be assessed. The arteries were transfected for 2 h with the pE9iNOS or CMViNOS constructs and the responsiveness to PE measured again. Control sections were perfused with transfection agent alone. A reduced responsiveness to PE is indicative of a greater generation of the vasodilator NO K . Artery sections transfected with the pE9iNOS construct showed the greatest reduction in responsiveness to PE. After the 1 h transfection period the response was only 2273% (P ¼ 0.00002) of control and this fell to 1772% (P ¼ 0.000005) after a further 1 h (Figure 2 ). Even after 1 h of exposure to the NOS inhibitor nitro-Larginine (L-NArg; 40 mM), there was no recovery of 
Growth delay in RIF1 tumours following pE9iNOS or CMViNOS gene transfer
Intradermal RIF-1 tumours were injected with the pE9iNOS/liposome complex. Figure 3 shows the growth curves of these tumours. Treatment effectiveness was assessed by calculating the time to reach three times the volume on the day of treatment. The growth delay achieved by each treatment compared to control is shown in Table 1 . Untreated control tumours reached three times their treatment volume after 4.2 days. Tumours treated with pE9iNOS took 11.1 days, while tumours treated with the constitutively expressed CMViNOS construct took 6.2 days. This difference between the two treatments was highly significant (P ¼ 0.004).
Levels of iNOS protein and nitrite in RIF1 tumours injected with the pE9iNOS construct
Protein levels were measured in tumours injected with the pE9iNOS construct and compared with noninjected control tumours. Figure 4 shows densitometric analysis of Western blots detecting iNOS protein levels. At 24 h after injection, tumours which received the pE9iNOS construct showed iNOS protein expression 3.7-fold higher (P ¼ 0.011) than in those tumours that were not injected, and by 48 h after injection this level was 4.5-fold higher than controls (P ¼ 0.03). Levels of iNOS protein remained elevated in transduced tumours over the 7-day time course. Nitrite levels in tumours were assessed using the Greiss test ( Figure 5 ). Nitrite levels in transduced tumours matched the increase in iNOS protein levels.
At 24 h after injection the nitrite level in transduced tumours was 6.2-fold higher than that observed in control tumours.
Discussion
Nitric oxide has great potential as an anticancer agent to augment current cancer therapy. It results in radiosensitisation of hypoxic cells, [23] [24] [25] and at high concentrations enhances apoptosis. 26 However, clinical use of NO K for cancer treatment strategies has been limited by the hypotension observed after systemic administration. 27 Transfer of the iNOS gene to tumour cells offers a way of generating high concentrations of NO K specifically within the tumour volume.
Control of transgene expression is of utmost importance in gene therapy particularly for strategies where the products are themselves toxic. The use of externally inducible promoters has been widely studied. 28, 29 The Egr1 promoter is well known to be transiently induced by ionising radiation 30 and the radioresponsive enhancer containing four CArG elements has been identified in the 5 0 distal region of the promoter. 22 In the present study, a synthetic enhancer consisting of nine directly repeated CArG elements 20 was assessed driving expression of the iNOS gene. One explanation is that iNOS expression generates NO K , which in turn induces the pE9 promoter, leading to higher levels of transgene expression via a positive feedback loop. In this model, promoter activation will be initiated by endogenous levels of NO K acting on pE9. This hypothesis is supported by the observation that the Egr1 gene is known to be induced by reactive oxygen intermediates, 22 but our data do not allow us to exclude other mechanisms.
Time after transfection (d) Tumour volume (mm3)
We next compared the ability of the E9 and CMV promoters to drive iNOS expression using an ex vivo perfusion system. At 1 h after gene transfer, artery sections which received the pE9iNOS gene had little contractile response to phenylephrine, while those transfected with CMViNOS exhibited an almost 90% response. This difference did not reflect the iNOS protein levels as measured in cultured human microvascular endotheial cells in which CMViNOS and pE9iNOS gave similar results (Figure 1 ). It should be noted, however, that the physiological end point, perfusion pressure (Figure 2) , is an exquisitely sensitive measure of changes in smooth muscle tone (it changes with the 4th power of the vessel diameter) so very small diameter changes mean large changes in pressure. Thus, small differences in the levels of NO K production would be amplified. In addition, the data in Figure 1 were obtained in immortalised endothelial cells in vitro whereas we have previously shown that transfection of a perfused artery results in transgene expression in all layers in the vessel. 11 By far the most abundant cell type in the artery is the smooth muscle cell, not the endothelial cell so direct, quantitative comparisons are probably not meaningful.
We have previously reported that transfection with CMViNOS or WAF1iNOS results in significant cytotoxicity in the murine RIF-1 tumour model. 12, 13 We repeated this study using the pE9iNOS construct, without any inducing dose of radiation. In a growth delay assay, tumours treated with pE9iNOS took 11.1 days to reach three times treatment volume, compared to 6.2 days for CMViNOS treatment and 4.2 days for untreated controls. This growth delay is greater than that previously observed with the WAF1 promoter in the absence of radiation. 13 Tumour growth delay was also observed in a recent study in HCT-116 colorectal cancer xenografts, in which an adenoviral constitutively driven iNOS construct was injected daily for 5 days. 31 While the antitumour effect was less than that seen in the present study using a single injecton of pE9iNOS, the fact that a different cell line was used prohibits a more detailed analysis of the mechanisms.
We measured iNOS protein expression by Western blotting in the tumour growth delay experiment: tumours receiving pE9iNOS had iNOS protein levels 3.7-fold higher than control untreated tumours 24 h after injection. This rise in iNOS protein levels was matched by a corresponding increase in nitrite levels within the tumour, 24 h after injection of pE9iNOS nitrite levels were 6.2 times higher than in untreated tumours. This is similar to increased nitrite levels observed in vitro after adenoviral transfer of a constitutively expressing iNOS construct. 31 The persistently high level of expression of iNOS in our experiments appears to be due to NO K activation of the E9 promoter. This property of the pE9iNOS construct makes it an attractive vector for use in gene therapy Evaluation of a synthetic CarG promoter J Worthington et al strategies for cancer, as constitutive expression of iNOS and NO K production are often higher in tumours than in normal tissues [32] [33] [34] by a mechanism that probably involves mutant p53. 35 iNOS gene transfer is becoming increasingly used in experimental models of solid tumours, with several groups reporting increased apoptosis in various tumour types including colorectal 31, 36 and gastric 37 carcinoma. On the basis of our findings the pE9iNOS gene construct is worthy of further investigation in cancer gene therapy strategies involving iNOS, since intrinsic, high-level expression is observed in a manner that is effective in vivo. To put this antitumour effect in perspective, while a single 20 Gy dose of X-rays increased the time for RIF1 tumours to grow to 3 Â their volume on the day of treatment by 3.0 days compared with untreated tumours, 13 a single intratumoural injection of 25 mg of pE9iNOS increased the time by 6.9 days.
A further level of specificity, such as incorporation of tissue-specific elements in the expression construct may be of benefit, though not necessarily a requirement of this strategy. Indeed, chimeric promoters containing E9 and hypoxia-responsive elements have already been shown to function, responding to both radiation and low oxygen tension. 21 Our previous studies have shown that with an intratumoural injection of DNA, specific vector sequences are detectable by PCR in various organs including, heart, lung, kidney and liver though not necessarily at the high concentrations found in the tumour. 13 Although not specifically measured in the present study, it is reasonable to assume that a similar distribution of vector DNA occurred, because the tumour model and lipid vector are identical. Of note then is the fact that although the iNOS gene was probably present at low levels in normal tissues, and that fairly uncontrolled gene expression is observed with the pE9iNOS construct, the therapy was well tolerated. However, sufficient NO K was generated within the tumour volume, even in the absence of radiation, to elicit an E9iNOS vector-mediated therapeutic effect. One possible explanation for a therapeutic gain is that higher NO K levels are generated in the tumour. High levels of NO K , combined with high endogenous levels of superoxide in tumours, induce peroxynitrite-mediated activation of apoptoic pathways, 38 whereas at low levels, rather than having a toxic effect, NO K is reported to protect cells from oxidative damage 39, 40 and any systemic hypotensive action on the vasculature can be compensated by numerous other physiological pathways.
This study demonstrates the potential of the E9 promoter for use in iNOS gene therapy in solid tumours. Further evaluation in combination with radiation in clinically relevant protocols is now warranted.
Materials and methods

Cell culture
Human micro-vascular endothelial cells, HMEC-1 (a kind gift from Dr E Ades, Centres for Disease Control, Atlanta, GA, USA) were routinely maintained in MCDB131 medium (Invitrogen Ltd, Paisley, UK) supplemented with foetal bovine serum (10%) (PAA Laboratories Ltd, Yeovil, UK), endothelial growth factor (10 ng/ ml) (Invitrogen Ltd), hydrocortisone (1 ml/ml) (SigmaAldrich Company Ltd, Gillingham, Dorset, UK) and Lglutamine (10 mM) (Invitrogen Ltd).
RIF-1 murine fibrosarcoma cells were rountinely maintained in RPMI 1640 medium (Gibco BRL, Paisley, UK) supplemented with foetal bovine serum (15%). Cells were grown as monolayers at 371C under 5% CO 2 /95% air and passaged every 3-4 days to maintain exponential growth.
Vector constructs
The CMViNOS and pE9iNOSpuro constructs were cloned as previously described. 12, 18, 20 The CMViNOS expression vector was digested with Nhe1 and Not1 to release the iNOS gene, which was cloned directionally into the pE9GFPpuro vector 21 after removal of the GFP gene.
In vitro transfections
HMEC-1 cells (1 Â 10 5 ) were seeded into 35 mm Petri dishes (Nalge-Nunc Ltd, Hereford, UK). After 12 h, the cells were transfected with various expression constructs using Lipofectin (Invitrogen Ltd) according to the manufacturers instructions. The NOS inhibitor N G monomethyl-L-arginine (L-NMMA; 40 mM) was added to one group at the time of transfection.
Preparation of rat artery specimens
Rat tail artery segments were prepared from normotensive adult male Wistar rats (250-350 g) as previously described.
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Transfection of the tail artery segments was carried out using the lipid reagent Tfx-50 (Promega Corporation, Madison, USA). In all, 25 mg of CMViNOS or pE9iNOS-puro was circulated through the artery in 10 ml of Krebs' solution for 2 h. Next, arteries were perfused with Krebs' solution supplemented with tetrahydrobiopterin (BH 4 ; 1 Â 10 À5 M), which had previously been shown to be essential for optimal NO K production after NOS gene transfer. Responsiveness of the artery segments was tested by perfusion with the vasoconstrictor phenylephrine (2 Â 10 À5 M). This concentration had previously been shown to yield maximal contraction/constriction.
Growth delay of RIF-1 tumours
Tumours for in vivo experiments were obtained by intradermal injection of 2 Â 10 5 cells (in a volume of 0.05 ml of PBS) on the rear dorsum of lightly anaesthetised (isofluorane inhalation) 10-12-week-old female C3H mice. Mice were treated when tumours reached a volume of 150-250 mm 3 assessed by calliper measurement. All animal experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986 and conformed to the current UKCCCR guidelines.
When tumours reached appropriate size, mice were assigned to treatment groups: no treatment, empty vector, CMViNOS or pE9iNOSpuro. 
Western blotting
In vitro samples for protein analysis were extracted by lysing with Laemmli buffer (Sigma-Aldrich Company Ltd), while in vivo protein samples were obtained by Trizol (Invitrogen Ltd) extraction of protein from the tumour.
In all, 30 mg of each sample was electrophoresed through a 10% SDS-polyacrylamide gel, transferred to nitrocellulose membrane (Hybond C, Amersham Biosciences UK Limited, Chalfont St Giles, UK) and probed with anti-iNOS (Cambridge Bioscience Ltd, Cambridge, UK). Levels of gene expression were assessed using an ECL detection kit (Amersham Biosciences UK Ltd). Densitometry was carried out on the samples using Kodak analysis software to assess the intensity of each band on the autoradiograph.
NO
K detection
The release of NO was measured using a Nitric Oxide Quantification Kit (Active Motif Inc., Rixensart, Belgium), which utilises a Greiss-based assay to measure nitrite levels as a function of time. The assay was carried out according to manufacturer's instructions in a 96-well plate, with measurements performed at 540 nm using a Genios plate reader (Tecan Systems Inc., San Jose, CA, USA).
